2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.03 Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

EP.13B.03 Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Back to course

Pdf Summary

The study led by Apar K. Ganti and colleagues examined the real-world outcomes of using a combination of platinum-based chemotherapy and immunotherapy (IO) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The research aimed to assess the demographics, clinical characteristics, treatment patterns, and outcomes in this patient population outside of clinical trials.<br /><br />The study leveraged data from a de-identified electronic health record-derived database from Flatiron Health, including 1144 patients who received first-line treatment with platinum and immunotherapy. A significant proportion of these patients, 764 individuals, also received maintenance IO treatment.<br /><br />Key findings highlighted the median real-world overall survival (rwOS) for the entire cohort as 10.4 months and 13.1 months for those in the maintenance group. Maintenance IO showed slightly favorable survival outcomes, with median rwOS from the start of maintenance IO at 9.7 months. The median progression-free survival (rwPFS) was also reported, displaying similar trends between the induction and maintenance groups.<br /><br />The study noted the adverse events of special interest (AESIs), which were commonly hematologic toxicities with induction platinum-IO. Grade 3 toxicities like neutropenia and anemia were prevalent in about a third of the patients, while these events were less frequent during maintenance IO.<br /><br />Ultimately, the study's findings confirmed comparable effectiveness to results seen in clinical trials like IMpower133 and CASPIAN, despite poorer baseline prognostic factors in the real-world cohort. However, it emphasized the ongoing need for more effective first-line treatment options due to low survival outcomes. The researchers acknowledged potential limitations, including data incompleteness and selection biases. Despite this, the results support the use of maintenance IO with atezolizumab or durvalumab for treating ES-SCLC.

Asset Subtitle

Apar Kishor Ganti

Meta Tag

Speaker Apar Kishor Ganti

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

platinum-based chemotherapy

immunotherapy

small cell lung cancer

real-world outcomes

maintenance treatment

overall survival

progression-free survival

adverse events

clinical trials

treatment effectiveness